Free Trial

Farther Finance Advisors LLC Sells 4,660 Shares of The Clorox Company (NYSE:CLX)

Clorox logo with Consumer Staples background
Remove Ads

Farther Finance Advisors LLC decreased its stake in The Clorox Company (NYSE:CLX - Free Report) by 49.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 4,682 shares of the company's stock after selling 4,660 shares during the quarter. Farther Finance Advisors LLC's holdings in Clorox were worth $760,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of CLX. State Street Corp increased its stake in Clorox by 3.1% in the 3rd quarter. State Street Corp now owns 8,182,109 shares of the company's stock valued at $1,332,947,000 after buying an additional 245,525 shares during the period. Mizuho Securities USA LLC increased its stake in Clorox by 46,877.8% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company's stock valued at $733,095,000 after buying an additional 4,490,421 shares during the period. Geode Capital Management LLC increased its stake in Clorox by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,028,333 shares of the company's stock valued at $491,713,000 after buying an additional 33,970 shares during the period. Stifel Financial Corp increased its stake in Clorox by 1.7% in the 3rd quarter. Stifel Financial Corp now owns 2,334,826 shares of the company's stock valued at $380,370,000 after buying an additional 37,967 shares during the period. Finally, Amundi increased its stake in Clorox by 42.6% in the 4th quarter. Amundi now owns 1,032,283 shares of the company's stock valued at $165,816,000 after buying an additional 308,234 shares during the period. Institutional investors and hedge funds own 78.53% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

CLX has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price target on shares of Clorox from $171.00 to $173.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Barclays raised their target price on shares of Clorox from $130.00 to $140.00 and gave the company an "underweight" rating in a research note on Wednesday, February 5th. Evercore ISI raised their target price on shares of Clorox from $145.00 to $155.00 in a research note on Tuesday, February 4th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $150.00 target price on shares of Clorox in a research note on Thursday, January 30th. Finally, Wells Fargo & Company raised their target price on shares of Clorox from $157.00 to $161.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 4th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $159.62.

Read Our Latest Analysis on CLX

Clorox Price Performance

Shares of CLX traded up $0.45 during trading hours on Wednesday, hitting $145.33. 1,104,698 shares of the company were exchanged, compared to its average volume of 1,215,082. The company has a market cap of $17.90 billion, a price-to-earnings ratio of 39.71, a P/E/G ratio of 2.62 and a beta of 0.45. The Clorox Company has a fifty-two week low of $127.60 and a fifty-two week high of $171.37. The company has a quick ratio of 0.60, a current ratio of 0.94 and a debt-to-equity ratio of 20.52. The firm's fifty day moving average is $153.71 and its 200 day moving average is $160.08.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, February 3rd. The company reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.16. Clorox had a return on equity of 316.87% and a net margin of 6.38%. During the same quarter last year, the company posted $2.16 EPS. On average, equities analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Wednesday, April 23rd will be paid a $1.22 dividend. This represents a $4.88 annualized dividend and a yield of 3.36%. The ex-dividend date is Wednesday, April 23rd. Clorox's dividend payout ratio (DPR) is presently 133.33%.

Clorox Company Profile

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Featured Stories

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Should You Invest $1,000 in Clorox Right Now?

Before you consider Clorox, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.

While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Time to Buy SoFi? Fintech’s Next Big Move
3 Chip Stocks Primed for a Comeback—Have They Found the Bottom?
Why Palantir’s Future Just Got a Massive Boost

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads